SecBot SecBot
425 ·Filed Nov 2, 2026

INM

InMed Pharmaceuticals Inc.
NEUTRAL
Impact 3/10
Horizondays Processed14d 9h ago SEC0001193125-26-443834
Rule 425 M&A communications
Actionable Insight • Neutral

Monitor the November 4 shareholder meeting results for approval of the three proposals, which are prerequisites for the consolidation and the merger. The merger timeline remains contingent on these approvals.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$1.68
T+0 close · Nov 2, 2026 · via day close
Latest settled
−7.38%
T+5 · $1.56 · next T+20 in 15d
Vs SPY
−6.79%
α at T+5
Latest observation
+14.04%
T+8 · FF3 residual α
  1. T+0 · Nov 3 $1.68entry
  2. T+1 · 13d ago +4.17%α +2.51% · $1.75
  3. T+5 · 7d ago −7.38%α −6.79% · $1.56
  4. T+9 · todayOpen
  5. T+20 · in 15d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

InMed announced a 1-for-10 share consolidation conditional on shareholder approval of three proposals at the November 4, 2026 meeting. The consolidation is a procedural step to facilitate the pending merger with Mentari Therapeutics, reducing outstanding shares from 5,493,735 to approximately 549,374. No changes to deal terms or financials were disclosed.

Key Financial Metrics

Deal Type
merger

Key Facts

  • InMed announced a 1-for-10 share consolidation, reducing outstanding shares from 5,493,735 to approximately 549,374.
  • The consolidation is conditional on shareholder approval of the Nasdaq Share Issuance Proposal, Return of Capital Proposal, and Redomestication Proposal at the November 4, 2026 meeting.
  • The consolidation is expected to be completed after market close on November 4, 2026, with post-consolidation shares trading on Nasdaq on November 5, 2026.
  • This is a procedural step in the previously announced merger with Mentari Therapeutics, with no changes to deal terms or financials.

Financial Impact

No direct financial impact; share consolidation reduces share count from 5,493,735 to ~549,374 but does not change shareholder percentage ownership or company value.

share count

Risk Factors

  • Shareholder approval of the three proposals is required; failure to obtain approval would prevent the consolidation and could delay or jeopardize the merger.
  • The consolidation is a reverse stock split that may affect liquidity and trading patterns, though it does not change fundamental value.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
425 Filing (Primary)0001193125-26-443834
Document: 0001193125-26-443834-index-headers.html0001193125-26-443834
Document: 0001193125-26-443834-index.html0001193125-26-443834
Document: 0001193125-26-443834.txt0001193125-26-443834

Track record

22 reports on INM

Performance horizon

6 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +24.51% at T+1 after the Nov 3, 2026 report. 10 of 12 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K Neutral 5/10 Entry $16.00 Now $19.87 +24.19% settles Dec 8
  2. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
  3. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
  4. Nov 3, 202613d ago 8-K Bearish 6/10 Entry $1.75 Now $19.87 −1035.43% settles Dec 3
  5. Nov 2, 202614d ago 425 Neutral 3/10 Viewing Entry $1.68 Now $19.87 +1082.74% settles Dec 2
  6. Oct 26, 202621d ago 425 Neutral 3/10 Entry $1.59 Now $19.87 +1149.69% settles Nov 24
  7. Oct 7, 20265w ago SC 13G/A Bullish 5/10 Entry $1.33 to $1.32 Now $19.87 +1393.99% ▼ −0.68% +4.61% vs SPY
  8. Oct 2, 20266w ago EFFECT Neutral 3/10 Entry $1.33 to $1.60 Now $19.87 +1393.99% ▲ +20.30% +22.11% vs SPY
  9. Sep 18, 20268w ago 8-K Bearish 6/10 Entry $1.38 to $1.37 Now $19.87 −1339.86% ▲ +1.06% +0.15% vs SPY
  10. Sep 9, 20269w ago 425 Neutral 6/10 Entry $1.31 to $1.33 Now $19.87 +1416.79% ▲ +1.53% −0.60% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 2, 2026